Urinary Hypoxanthine as a Measure of Increased ATP Utilization in Late Preterm Infants

Megan S Holden1, Andrew Hopper1, Laurel Slater1

  • 1Departments of Basic Sciences (MSH, LS, YA, DSB, DA) and Pediatrics (AH), Loma Linda University School of Medicine; Department of Earth and Biological Sciences, Loma Linda University School of Public Health (IE), Loma Linda, California.

Insights

Neonatal respiratory disorders significantly increase adenosine triphosphate (ATP) breakdown in late preterm infants. This breakdown is indicated by higher urinary hypoxanthine levels, a key marker.

Area of Science:

  • Biochemistry
  • Neonatal Medicine
  • Pediatrics

Background:

  • Adenosine triphosphate (ATP) breakdown is a marker of cellular stress.
  • Late preterm infants are vulnerable to various morbidities.
  • Understanding metabolic changes in sick neonates is crucial for clinical management.

Purpose of the Study:

  • To investigate the impact of neonatal morbidities on ATP breakdown in late preterm infants.
  • To assess ATP breakdown using urinary hypoxanthine as a biomarker.
  • To correlate specific neonatal diagnoses with the extent of ATP degradation.

Main Methods:

  • Urinary hypoxanthine concentration was measured in 82 late preterm infants.
  • High-performance liquid chromatography was used for quantification.
  • Infants were categorized by diagnoses: poor nippling, hyperbilirubinemia, and respiratory disease.

Main Results:

  • Infants with respiratory disease alone exhibited significantly higher urinary hypoxanthine levels.
  • Higher hypoxanthine levels were observed in infants with respiratory disease compared to those with poor nippling or hyperbilirubinemia.
  • Increased respiratory support duration correlated with elevated hypoxanthine concentrations.

Conclusions:

  • Respiratory disorders are a significant factor in increased ATP degradation in late preterm infants.
  • Urinary hypoxanthine serves as a valuable indicator of metabolic stress in this population.
  • These findings highlight the metabolic consequences of respiratory compromise in neonates.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
333
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
375
ATP Yield01:31

ATP Yield

Cellular respiration produces 30 - 32 ATP per glucose molecule. Although most of the ATP results from oxidative phosphorylation and the electron transport chain (ETC), 4 ATP are gained beforehand (2 from glycolysis and 2 from the citric acid cycle).
The ETC is embedded in the inner mitochondrial membrane and is comprised of four main protein complexes and an ATP synthase. NADH and FADH2 pass electrons to these complexes, which pump protons into the intermembrane space. This distribution of...
80.6K